Literature DB >> 12607099

Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies.

E Varecková1, V Mucha, S A Wharton, F Kostolanský.   

Abstract

The effect of seven monoclonal antibodies (MAbs) specific to the light chain (HA2) of influenza A haemagglutinin (HA) on its fusion activity was investigated. These MAbs, which are non-virus neutralizing, defined four distinct antigenic sites on HA2 glycopolypeptide and the corresponding epitopes were attributed to the sequence stretches on HA2. The accessibility of all seven HA2 epitopes significantly increased after trypsin cleavage and pH 5 treatment of the HA (X-31). The influence of anti-HA2 MAbs on the fusion process was followed by cell-cell fusion of CHO cells expressing precursor HA, virus-liposome fusion assay, and haemolysis mediated by virus. MAb CF2, which bound directly to the fusion peptide 1-35 of HA2, was positive in all three fusion-inhibition assays and was the only one inhibiting the polykaryon formation of CHO-X-31 cells. Two other MAbs belonging to the same antigenic site but not binding directly to the fusion peptide inhibited virus to liposome fusion (EB12) or inhibited haemolysis (BB8). Moreover, MAb IIF4 binding to distinct antigenic site within 125-175 HA2 inhibited haemolysis, too. Thus, fusion activity of HA may be inhibited by anti-HA2 MAbs, mainly those binding to or near the fusion peptide. These antibodies represent useful probes for studies of influenza virus to cell membrane fusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12607099     DOI: 10.1007/s00705-002-0932-1

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  18 in total

1.  Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection.

Authors:  Zuzana Staneková; Vojtech Mucha; Tatiana Sládková; Hana Blaškovičová; František Kostolanský; Eva Varečková
Journal:  Influenza Other Respir Viruses       Date:  2012-01-12       Impact factor: 4.380

2.  A highly conserved neutralizing epitope on group 2 influenza A viruses.

Authors:  Damian C Ekiert; Robert H E Friesen; Gira Bhabha; Ted Kwaks; Mandy Jongeneelen; Wenli Yu; Carla Ophorst; Freek Cox; Hans J W M Korse; Boerries Brandenburg; Ronald Vogels; Just P J Brakenhoff; Ronald Kompier; Martin H Koldijk; Lisette A H M Cornelissen; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Ian A Wilson; Jaap Goudsmit
Journal:  Science       Date:  2011-07-07       Impact factor: 47.728

3.  FUBAR: a fast, unconstrained bayesian approximation for inferring selection.

Authors:  Ben Murrell; Sasha Moola; Amandla Mabona; Thomas Weighill; Daniel Sheward; Sergei L Kosakovsky Pond; Konrad Scheffler
Journal:  Mol Biol Evol       Date:  2013-02-18       Impact factor: 16.240

4.  Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.

Authors:  Junwei Li; Maria T Arévalo; Yanping Chen; Olivia Posadas; Jacob A Smith; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

5.  Structural basis for the divergent evolution of influenza B virus hemagglutinin.

Authors:  Fengyun Ni; Elena Kondrashkina; Qinghua Wang
Journal:  Virology       Date:  2013-08-27       Impact factor: 3.616

Review 6.  Structural basis of influenza virus neutralization.

Authors:  Thomas Han; Wayne A Marasco
Journal:  Ann N Y Acad Sci       Date:  2011-01-11       Impact factor: 5.691

7.  Characterization of the infectious salmon anemia virus fusion protein.

Authors:  Vidar Aspehaug; Aase B Mikalsen; Michael Snow; Eirik Biering; Stéphane Villoing
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 8.  Passive immune neutralization strategies for prevention and control of influenza A infections.

Authors:  Jianqiang Ye; Hongxia Shao; Daniel R Perez
Journal:  Immunotherapy       Date:  2012-02       Impact factor: 4.196

9.  Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Erin Petersen; Thomas M Moran; Peter Palese
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

10.  Novel hemagglutinin-based influenza virus inhibitors.

Authors:  Xintian Shen; Xuanxuan Zhang; Shuwen Liu
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.